A critical appraisal of the premotor symptoms of Parkinson's disease: potential usefulness in early diagnosis and design of neuroprotective trials.
about
Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons LearnedFunctional neuroimaging in Parkinson's diseaseBehavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease.Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and DiagnosisImpaired trunk stability in individuals at high risk for Parkinson's diseasePremotor Symptoms as Predictors of Outcome in Parkinsons Disease: A Case-Control StudyThe diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: a systematic review.Cognitive frailty.Defining at-risk populations for Parkinson's disease: lessons from ongoing studies.Pathogenesis of Parkinson disease--the gut-brain axis and environmental factors.Brain pathology contributes to simultaneous change in physical frailty and cognition in old ageMeta-analyses on prevalence of selected Parkinson's nonmotor symptoms before and after diagnosisRisk of premotor symptoms in patients with newly diagnosed PD: a nationwide, population-based, case-control study in Taiwan.Nonmotor symptoms in Parkinson's disease in 2012: relevant clinical aspects.Idiopathic REM sleep behaviour disorder in the development of Parkinson's diseaseCognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease.Delineating nonmotor symptoms in early Parkinson's disease and first-degree relativesResearch on the premotor symptoms of Parkinson's disease: clinical and etiological implications.Neuropathological Staging of Brain Pathology in Sporadic Parkinson's disease: Separating the Wheat from the Chaff.Motor signs in the prodromal phase of Parkinson's disease.Lewy pathology and neurodegeneration in premotor Parkinson's disease.Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease?Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed?The pathomechanisms underlying Parkinson's disease.Nocturnal journey of body and mind in Parkinson's disease: the manifestations, risk factors and their relationship to daytime symptoms. Evidence from the NIGHT-PD study.Neuropathobiology of non-motor symptoms in Parkinson disease.Review: Sporadic Parkinson's disease: development and distribution of α-synuclein pathology.Prodromal symptoms and early detection of Parkinson's disease in general practice: a nested case-control study.Risk factors and prodromal markers and the development of Parkinson's disease.Potential impact of self-perceived prodromal symptoms on the early diagnosis of Parkinson's disease.In vivo gastric detection of α-synuclein inclusions in Parkinson's disease.Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.Parkinson's Disease from the Gut.Autonomic dysfunction in subjects at high risk for Parkinson's disease.Nonmotor symptoms and health-related quality of life in early Parkinson's disease.Cohort Profile: a population-based cohort to study non-motor symptoms in parkinsonism (EPIPARK).Serum uric acid in patients with Parkinson's disease and vascular parkinsonism: a cross-sectional study.Quantitative expression proteomics and phosphoproteomics profile of brain from PINK1 knockout mice: insights into mechanisms of familial Parkinson's disease.The spectrum of preclinical gait disorders in early Parkinson's disease: subclinical gait abnormalities and compensatory mechanisms revealed with dual tasking.
P2860
Q26738357-BB624F7D-0468-4E87-8100-4DE676E12908Q27013767-85EF6D52-C6CE-410D-9BDC-A4B02AE5444AQ27310355-816A1123-F7B9-47C4-ABB7-2C3B96217844Q28384572-73C27772-F6BF-4DB0-884A-2A22C001ED50Q28730962-69A99E90-BA78-4437-9309-9D398AC25F8EQ30356954-4E94C1CF-559C-4B22-8B99-B5DB2FCAEB6EQ30635471-15B05CA2-EEED-4488-9DF9-E2152612D014Q33804945-7DCF118C-127C-4A8F-A594-C2DB816C037CQ34234632-6EB11D9C-40EB-4B1B-84B2-9D83E4A657BDQ34674177-EDF96F6F-2682-425A-A76A-D69EABEC6EB6Q34974541-A7CDA570-7525-4D27-9A8B-FDE014C6AAB7Q35066107-16C2A1ED-3CF7-47FE-90F3-85F127CB96F8Q35673280-63B1224F-7377-4CC2-A453-E17713CE5C02Q36135045-7D1C90C1-7185-40FF-9CA3-A3C7512C77A7Q36656691-E5A8D5E4-3524-4A51-84FD-6FF10E16859AQ36865849-F832E45C-78E7-45CB-84FC-CAAE09C22B80Q37279420-42BF6E4F-C377-4ABE-B134-1E4ECCBD7374Q37374203-46413893-C0B6-45F0-991D-568FC51C1945Q37693339-9DA3F09D-EA05-452E-9211-D2C7891EEB16Q37995956-9C8E8581-9CCC-493D-A7EC-894CD3508D62Q38003064-97E31188-357A-4BFD-BA79-7B0CCAE21C47Q38014888-93049CF3-8646-4DD5-B8BE-59B0008EA4D1Q38021661-D1D9F239-010E-4E72-8F7E-2F330FA19230Q38182660-6E848882-D488-4C93-8FBE-ECA2CE6EFDE5Q38200511-5B0F2E8C-C53D-4E74-A45E-E6AB97717F9DQ38481481-D0CAD57F-023F-4D94-9B60-CF13955C6AAAQ38667942-44687E9F-B576-4019-A928-ABDC43D92FBBQ39185499-444BD84F-EA9A-4E90-B4E4-E70A9DB5DE13Q44252207-A9907BD0-8DCF-4941-A2C6-EF6B1CCC252DQ45337355-D615684F-6110-4F5D-93ED-8B2AF6219F03Q46245987-869B159F-1881-4E42-AEA1-D5C3C768762AQ46354756-D47EA59B-C27C-4E96-9395-2C29CA99A808Q47649089-B7D7D6C7-AC8A-47F7-B0B4-DD33C1103354Q48071243-3F840E09-7675-4B24-A21E-1FDB75A73C26Q48105952-EA1D317B-0588-4423-8AB0-8E90AE5E6C10Q48204968-FF1C86CC-343F-44E4-B5F3-3209AFF0DDBCQ48212390-0F059578-BFC2-4A2B-AC92-82B4B4BD5E4DQ48357636-E391E9F3-BD24-4CA0-A61D-2483CBB4C6E6Q50489508-F90C143D-4CBC-4DB6-A1B8-0FB359C3290E
P2860
A critical appraisal of the premotor symptoms of Parkinson's disease: potential usefulness in early diagnosis and design of neuroprotective trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A critical appraisal of the pr ...... ign of neuroprotective trials.
@en
A critical appraisal of the pr ...... ign of neuroprotective trials.
@nl
type
label
A critical appraisal of the pr ...... ign of neuroprotective trials.
@en
A critical appraisal of the pr ...... ign of neuroprotective trials.
@nl
prefLabel
A critical appraisal of the pr ...... ign of neuroprotective trials.
@en
A critical appraisal of the pr ...... ign of neuroprotective trials.
@nl
P2860
P356
P1433
P1476
A critical appraisal of the pr ...... ign of neuroprotective trials.
@en
P2860
P304
P356
10.1002/MDS.23609
P407
P50
P577
2011-04-11T00:00:00Z